Integrum AB

The company's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage position. However, the liquidity risk is rated as medium, and the company has negative free cash flow of -36,158,690 SEK, suggesting potential challenges in maintaining liquidity without external financing. The current ratio of 4.54 indicates strong short-term liquidity, with current assets significantly outpacing current liabilities.

Profitability metrics are concerning, with a return on equity of -17.35% and a return on assets of -15.18%, both well below the industry median for medical equipment and supplies firms. The company reported a net loss of -30,816,930 SEK and an operating loss of -42,126,080 SEK, reflecting significant operational inefficiencies or cost overruns. Gross profit of 75,381,990 SEK is positive but insufficient to cover operating expenses, indicating a need for cost optimization or revenue diversification.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts. No material revenue contributions from international markets are reported, suggesting a domestic focus that could limit growth potential.

The company's growth trajectory is mixed. Analysts estimate a revenue increase to 110,900,000 SEK in the next fiscal year, a 21.7% year-over-year increase. However, the company's operating cash flow remains negative, and the mean EPS estimate is -1.97 SEK, indicating continued losses. The company's capital expenditures of -11,887,460 SEK suggest ongoing investment in infrastructure, but the negative free cash flow implies these investments are not yet generating returns.

Risk factors include a medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is rated as low, with no significant dilution expected in the near term. The company's financial performance and operational losses raise concerns about its ability to sustain operations without additional capital or strategic adjustments.

Recent events include a consistent price target of 32.58 SEK from analysts, with no variation in high or low estimates. The last actual EPS was -1.43 SEK, below the mean estimate of -1.97 SEK, suggesting a potential for further earnings deterioration. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational changes.